Journal Mobile Options
Table of Contents
Vol. 73, No. 1-2, 2007
Issue release date: March 2008
Oncology 2007;73:52–57

Colorectal Cancer or Colon and Rectal Cancer?

Clinicopathological Comparison between Colonic and Rectal Carcinomas

Li M. · Li J.Y. · Zhao A.L. · Gu J.
aGastrointestinal Surgery Unit, and bDepartment of Pathology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Aims: The aim of this study was to compare features of colon and rectal cancers such as prognosis, clinicopathological features and tumor markers, namely carcinoembryonic antigen (CEA), matrix metalloproteinase (MMP)-2 and p27kip1. Methods: Two hundred and thirty patients with stage I–III colon or rectal cancer were retrospectively assessed with the endpoint of recurrence or metastasis after curative operation. CEA, MMP-2 and p27kip1 were studied by immunohistochemistry in cancer tissues of all patients. Results: The disease-free 3-year survival rate after operation of the total 230 patients was 63.0%. The prognosis of colon cancer was significantly better than that of rectal cancer (70.6 vs. 57.0%; p = 0.017), especially for stage III (p = 0.0059). Multivariate analysis also demonstrated that tumor location in the colon or rectum, differentiation, venous invasion and the expression of CEA were independent factors for prognosis. The hazard of recurrence and metastasis in rectal cancer was 1.564 times that in colon cancer. In both groups, there were no statistical differences in age, gender, tumor size, tumor gross type, mucin production, tumor differentiation, venous invasion, MMP-2 and p27kip1. Conclusion: We investigated prognosis, clinicopathological factors, oncogenes and tumor suppressor gene production in colon and rectal cancers. The prognosis of colon cancer is better than that of rectal cancer, especially for stage III. This study shows some differences between colon and rectal cancer.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  2. American Joint Committee on Cancer: Cancer Staging Manual, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 83–88.
  3. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva, WHO, 2006.
  4. Leeman MF, McKay JA, Murray GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002;55:758–762.
  5. Lyall MS, Dundas SR, Curran S, Murray GI: Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006;12:1184–1191.
  6. Kim JC, Roh SA, Kim HC, Koo KH, Cho YK, Yu CS, Kwon YM, Kim JS: Coexpression of carcinoembryonic antigen and E-cadherin in colorectal adenocarcinoma with liver metastasis. J Gastrointest Surg 2003;7:931–938.
  7. Araki K, Furuya Y, Kobayashi M, Matsuura K, Ogata T, Isozaki H: Comparison of mucosal microvasculature between the proximal and distal human colon. J Electron Microsc (Tokyo) 1996;45:202–206.
  8. Skinner SA, O’Brien PE: The microvascular structure of the normal colon in rats and humans. J Surg Res 1996;61:482–490.
  9. Devesa SS, Chow WH: Variation in colorectal cancer incidence in the United States by subsite of origin. Cancer 1993;71:3819–3826.
  10. Shamsuddin AM, Phelps PC, Trump BF: Human large intestinal epithelium: light microscopy, histochemistry, and ultrastructure. Hum Pathol 1982;13:790–803.
  11. Macfarlane GT, Gibson GR, Cummings JH: Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol 1992;72:57–64.
  12. Mercurio MG, Shiff SJ, Galbraith RA, Sassa S: Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects. Biochem Biophys Res Commun 1995;210:350–355.
  13. Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A, Iacopetta B: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 1997;3:1405–1411.
  14. Sun XF, Carstensen JM, Zhang H, Arbman G, Nordenskjold B: Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 1996;32A:1963–1967.
  15. Gonzalez EC, Roetzheim RG, Ferrante JM, Campbell R: Predictors of proximal vs distal colorectal cancers. Dis Colon Rectum 2001;44:251–258.
  16. Heald RJ, Moran BJ: Embryology and anatomy of the rectum. Semin Surg Oncol 1998;15:66–71.
  17. Wiggers T, Arends JW, Verstijnen C, et al: Prognostic significance of CEA immunoreactivity patterns in large bowel carcinoma tissue. Br J Cancer 1986;54:409–414.
  18. Kitadai Y, Radinsky R, Bucana CD, et al: Regulation of carcinoembryonic antigen expression in human colon carcinoma cells by the organ microenvironment. Am J Pathol 1996;149:1157–1166.
  19. Jessup JM, Petrick AT, Toth CA, Ford R, Meterissian S, O’Hara CJ, Steele G Jr, Thomas P: Carcinoembryonic antigen: enhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer 1993;67:464–470.
  20. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, Oettgen HF: Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978;299:448–451.
  21. Cosimelli M, De Peppo F, Castelli M, Giannarelli D, Schinaia G, Castaldo P, Buttini GL, Sciarretta F, Bigotti G, Di Filippo F, et al: Multivariate analysis of a tissue CEA, TPA, and CA 19.9 quantitative study in colorectal cancer patients. A preliminary finding. Dis Colon Rectum 1989;32:389–397.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50